RxDoctor Payments Data

Shelby Laughlin, MD

Family Medicine · Ozark, MONPI 1821659699

Payments from drug & device makers

$3,688in general payments, 2019–2025

Across 216 payments — averaging $17.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$612
  • Novo Nordisk$586
  • AstraZeneca$473
  • Pfizer$301
  • AbbVie$244
  • Takeda Pharmaceuticals U.S.A., Inc.$200
  • plus $1K from 22 others

What the payments were for

  • Food & beverage$3,688100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,688 in reported general payments places this provider in the 80th percentile of 2,203 family medicine providers in Missouri.

See all family medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$21,959
Medicare patients
95
Services billed
342

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide36$35,440
MounjaroTirzepatide31$32,457
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$22,954
JanuviaSitagliptin Phosphate32$21,212
EliquisApixaban24$21,138
Spiriva RespimatTiotropium Bromide12$9,290
TradjentaLinagliptin12$8,568
ShingrixVaricella-Zoster Ge/As01b/Pf15$3,305
Arnuity ElliptaFluticasone Furoate13$2,734
Carvedilol ErCarvedilol Phosphate11$1,798
Gabapentin92$1,141
Albuterol Sulfate HfaAlbuterol Sulfate81$1,122
Boostrix TdapDiphth,pertuss(Acell),tet Vac11$755
Atorvastatin Calcium129$752
Amlodipine Besylate157$749

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$586$35,44036 claims
Lilly USA, LLCMounjaro$612$32,45731 claims
GSKTrelegy Ellipta, Shingrix, Arnuity Ellipta$80$28,99357 claims
MerckJanuvia$30$21,21232 claims
PfizerEliquis$301$21,13824 claims
Boehringer IngelheimSpiriva Respimat, Tradjenta$89$17,85724 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,203 family medicine providers in Missouri.

Other family medicine in Ozark

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →